Core Insights - MetaVia Inc. has announced a research collaboration with Syntekabio to enhance the therapeutic potential of its oral GPR119 agonist, DA-1241, by identifying additional disease targets and optimizing its therapeutic profile [1][3] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes (T2D) [6] - Syntekabio, a drug discovery company, utilizes AI-driven platforms to facilitate the rapid discovery of drug candidates and has a global network for validating computational results [5] Product Development - DA-1241 is a novel GPR119 agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, which are involved in glucose and lipid metabolism, as well as weight loss [4] - In a 16-week Phase 2a study involving 109 subjects, DA-1241 demonstrated a favorable safety and tolerability profile, along with hepatoprotective and glucose-regulating effects in patients with presumed MASH [2][4] Collaboration Details - The collaboration with Syntekabio will leverage its DeepMatcher® AI platform to conduct large-scale virtual screening against over 1,700 validated protein targets, aiming to uncover new indications for DA-1241 while minimizing off-target effects [3] - Initial insights from this collaboration are expected later in the year, which could further validate DA-1241's therapeutic potential [3]